21 U.S. Code § 379j–43 - Reauthorization; reporting requirements
prev | next
(a) Performance report
Beginning with fiscal year 2013, not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2012 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals.
(b) Fiscal report
Beginning with fiscal year 2013, not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.
(c) Public availability
The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.
In developing recommendations to present to the Congress with respect to the goals, and plans for meeting the goals, for human generic drug activities for the first 5 fiscal years after fiscal year 2017, and for the reauthorization of this subpart for such fiscal years, the Secretary shall consult with—
(2) Prior public input
Prior to beginning negotiations with the generic drug industry on the reauthorization of this subpart, the Secretary shall—
(B) hold a public meeting at which the public may present its views on the reauthorization, including specific suggestions for changes to the goals referred to in subsection (a);
(C) provide a period of 30 days after the public meeting to obtain written comments from the public suggesting changes to this subpart; and
(3) Periodic consultation
Not less frequently than once every month during negotiations with the generic drug industry, the Secretary shall hold discussions with representatives of patient and consumer advocacy groups to continue discussions of their views on the reauthorization and their suggestions for changes to this subpart as expressed under paragraph (2).
(4) Public review of recommendations
After negotiations with the generic drug industry, the Secretary shall—
(A) present the recommendations developed under paragraph (1) to the congressional committees specified in such paragraph;
(C) provide for a period of 30 days for the public to provide written comments on such recommendations;
(5) Transmittal of recommendations
Not later than January 15, 2017, the Secretary shall transmit to the Congress the revised recommendations under paragraph (4), a summary of the views and comments received under such paragraph, and any changes made to the recommendations in response to such views and comments.
(6) Minutes of negotiation meetings
(A) Public availability
Before presenting the recommendations developed under paragraphs (1) through (5) to the Congress, the Secretary shall make publicly available, on the Internet Web site of the Food and Drug Administration, minutes of all negotiation meetings conducted under this subsection between the Food and Drug Administration and the generic drug industry.
Source(June 25, 1938, ch. 675, § 744C, as added Pub. L. 112–144, title III, § 303,July 9, 2012, 126 Stat. 1022.)
Termination of Section
For termination of section by section 304(b) ofPub. L. 112–144, see Effective and Termination Dates note set out below.
References in Text
Section 301(b) of the Generic Drug User Fee Amendments of 2012, referred to in subsec. (a), is section 301(b) ofPub. L. 112–144, which is set out as a note under section 379j–41 of this title.
Effective and Termination Dates
Pub. L. 112–144, title III, § 304(b),July 9, 2012, 126 Stat. 1024, provided that: “Section 744C of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 379j–43], as added by section 303 of this Act, shall cease to be effective January 31, 2018.”
Section effective Oct. 1, 2012, see section 305 ofPub. L. 112–144, set out as a note under section 379j–41 of this title.
LII has no control over and does not endorse any external Internet site that contains links to or references LII.